Related Experiment Video
Updated: Jul 12, 2026

A Swine Burn Model for Investigating the Healing Process in Multiple Depth Burn Wounds
Published on: February 23, 2024
The uses of heparin to treat burn injury
Insights
This review found insufficient evidence to support heparin for burn treatment due to weak study quality. Further research is needed to determine heparin
Area of Science:
- Burn injury research
- Pharmacological interventions
- Evidence-based medicine
Background:
- Heparin is used for various medical conditions.
- Its application in burn injury treatment is under investigation.
- Non-anticoagulant properties of heparin are of interest.
Purpose of the Study:
- To systematically assess the available evidence on heparin's efficacy in treating burn injuries and their complications in adults and children.
- To evaluate the quality of existing studies investigating heparin for burn care.
Main Methods:
- Comprehensive literature search across multiple databases (MEDLINE, EMBASE, CINAHL, Cochrane, Web of Science, BIOSIS) and other sources.
- Two-level screening of titles and abstracts, followed by full-text review for eligible studies.
- Inclusion criteria: any language, human patients, any burn type/grade/TBSA, all heparin formulations and application methods, and studies with a comparison group.
Main Results:
- Nineteen articles from 18 unique studies were included, exploring various uses of heparin in burn care.
- The overall quality of the included studies was weak, with significant methodological limitations.
- Insufficient evidence exists to determine heparin's effectiveness in treating burn injury or its complications compared to other treatments.
Conclusions:
- The current body of evidence is inadequate to support the use of heparin for burn injury treatment based on its non-anticoagulant properties.
- Methodological weaknesses in existing studies hinder definitive conclusions.
- Contraindications for heparin use in burns include bleeding risks and allergies.
Objectives:
To assess the evidence for using heparin in the treatment of burn injury or the complications of burn injury in adults and children.
Data Sources:
The following databases were searched: MEDLINE (1966-current), EMBASE (1980-current), Cumulative Index to Nursing & Allied Health (CINAHL) (1982-current), The Cochrane Central Database of Controlled Trials (1995-current), Web of Science (1976-current), and BIOSIS (1976-current). Additional data sources included the U.S. and European Patent Offices, technical experts, the partner organization, and reference lists.
Review Methods:
Studies identified from the data sources went through two levels of title and abstract screening. Passing studies advanced to full text screening. Studies that met the full text screening criteria were abstracted. Criteria for abstraction included publication in any language, human patients of any age, and burns of any type, grade, or total body surface area. All formulations of heparin, and all application methods (e.g., topical, subcutaneous), were eligible for inclusion in the report. Abstracted studies required a comparison group. Outcomes of interest included mortality, pain, length of stay in hospital, thrombosis and emboli, psychiatric adjustment, and adverse effects (e.g., bleeding).
Results:
Nineteen articles from 18 unique studies were abstracted and included in this report. In these articles, there were multiple uses of heparin to treat burns (e.g., wound healing, inhalation injury, sepsis, pain). However, the overall quality of the articles was weak. Examples of weakness included unclear or inappropriate treatment allocation, no blinding, no control of confounding, poorly defined burn characteristics (e.g., thickness), unclear duration of treatment, incomplete description of heparin treatment, and use of inadequately described or invalid outcome measures. Overall, the evidence from these weak articles was insufficient to determine whether the effectiveness of heparin to treat burn injury was different from the effectiveness of other treatments, or whether treatment effectiveness varied according to (a) the method of applying heparin to (b) burn etiology. Four studies mentioned contraindications to using heparin to treat burns. These contraindications were bleeding diathesis, bleeding history, active bleeding or associated trauma with potential bleeding, active intestinal ulcer, thrombocytopenia, liver disease, renal disorders, or allergy to heparin.
Conclusions:
There is no strong evidence in the 19 abstracted articles to suggest that heparin should be used in the treatment of burn injury on account of its non-anticoagulant properties.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Burn Injuries
The damage results in the death of skin cells, which can lead to a massive loss of fluid. Dehydration, electrolyte imbalance, and renal and circulatory failure follow, which can be fatal. Burn patients are treated with intravenous fluids to offset...
Venous Thrombosis III: Interprofessional Care
Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Clinical Applications of Epidermal Stem Cells
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
